One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Comforting Data on the Incidence of Rectal Cancer After Subtotal Colectomy in IBD: The Risk Is Low, Yet Surveillance Matters!
Panu Wetwittayakhlang, Peter L Lakatos
doi : 10.1093/ecco-jcc/jjab084
Journal of Crohn's and Colitis, Volume 15, Issue 11, November 2021, Pages 1783–1784
Cannabis and Inflammatory Bowel Disease: All Smoke and Mirrors?
Robert J Gianotti, Adam S Cheifetz
doi : 10.1093/ecco-jcc/jjab091
Journal of Crohn's and Colitis, Volume 15, Issue 11, November 2021, Pages 1785–1786
Rectal Cancer Incidence is Low Following Rectal Diversion or Subtotal Colectomy for IBD: Results of a Population-based Study
Mantaj S Brar, Anthony de Buck van Overstraeten, Nancy N Baxter
doi : 10.1093/ecco-jcc/jjab090
Journal of Crohn's and Colitis, Volume 15, Issue 11, November 2021, Pages 1787–1798
Following subtotal colectomy or diversion for medically refractory inflammatory bowel disease [IBD], completion proctectomy has been recommended to reduce the risk of rectal cancer. However, this recommendation is based on low-quality evidence. Our objectives were to estimate the cumulative incidence of rectal cancer and evaluate if surveillance endoscopy reduces the risk of rectal cancer.
Oral CBD-rich Cannabis Induces Clinical but Not Endoscopic Response in Patients with Crohn’s Disease, a Randomised Controlled Trial
Timna Naftali, Lihi Bar-Lev Schleider, Shlomo Almog, David Meiri, Fred M Konikoff
doi : 10.1093/ecco-jcc/jjab069
Journal of Crohn's and Colitis, Volume 15, Issue 11, November 2021, Pages 1799–1806
Despite reports that medical cannabis improves symptoms in Crohn’s disease [CD], controlled studies evaluating disease response are lacking. This study assessed the effect of cannabidiol [CBD]-rich cannabis oil for induction of remission in CD.
Obesity in Inflammatory Bowel Disease Is Associated with Early Readmissions Characterised by an Increased Systems and Patient-level Burden
Simcha Weissman, Kirtenkumar Patel, Sindhura Kolli, Megan Lipcsey, Nabeel Qureshi, Sameh Elias, Aaron Walfish, Arun Swaminath, Joseph D Feuerstein
doi : 10.1093/ecco-jcc/jjab088
Journal of Crohn's and Colitis, Volume 15, Issue 11, November 2021, Pages 1807–1815
Rates of obesity are rising in patients with inflammatory bowel disease [IBD]. We conducted a US population-based study to determine the effects of obesity on outcomes in hospitalised patients with IBD.
Prevalence and Impact of Obesity on Disease-specific Outcomes in a Population-based Cohort of Patients with Ulcerative Colitis
Amanda M Johnson, W Scott Harmsen, Satimai Aniwan, William J Tremaine, Barham K Abu Dayyeh, Edward V Loftus, Jr
doi : 10.1093/ecco-jcc/jjab097
Journal of Crohn's and Colitis, Volume 15, Issue 11, November 2021, Pages 1816–1823
There remains a historical misconception that inflammatory bowel disease [IBD] patients are underweight. However, recent data suggest rates of obesity in IBD parallel to those of the general population. The impact obesity has on the natural history of IBD is unclear. We aimed to determine obesity rates at the time of IBD diagnosis in a population-based cohort of ulcerative colitis [UC] patients.
Association Between Inflammatory Bowel Disease and Psychiatric Morbidity and Suicide: A Swedish Nationwide Population-Based Cohort Study With Sibling Comparisons
Jonas F Ludvigsson, Ola Olén, Henrik Larsson, Jonas Halfvarson, Catarina Almqvist, Paul Lichtenstein, Agnieszka Butwicka
doi : 10.1093/ecco-jcc/jjab039
Journal of Crohn's and Colitis, Volume 15, Issue 11, November 2021, Pages 1824–1836
Inflammatory bowel disease [IBD] is linked to psychiatric morbidity, but few studies have assessed general population comparators. We aimed to investigate the risk of psychiatric morbidity and suicide in adult-onset IBD patients.
Acceptance and Perceived Control are Independently Associated With Quality of Life in Inflammatory Bowel Disease: Introduction of a New Segmentation Model
Liselot W van Erp, Jop van Gerven, Sjaak Bloem, Marcel J M Groenen, Peter J Wahab
doi : 10.1093/ecco-jcc/jjab082
Journal of Crohn's and Colitis, Volume 15, Issue 11, November 2021, Pages 1837–1845
Segmentation of patients based on psychological determinants of subjective health may provide new ways to personalized care. The cross-disease segmentation model developed by Bloem & Stalpers discriminates patients based on disease acceptance and perceived control. We aimed to validate the segmentation model, compare segments and evaluate whether segments independently correlate with quality of life in inflammatory bowel disease [IBD].
Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry
María Chaparro, Ana Garre, Marisa Iborra, Mónica Sierra-Ausín, Manuel Barreiro-de Acosta, Agnès Fernández-Clotet, Luisa de Castro, Maia Boscá-Watts, María José Casanova, Alicia López-García, Rufo Lorente, Cristina Rodríguez, Ana Y Carbajo, Maria Teresa Arroyo, Ana Gutiérrez, Joaquín Hinojosa, Teresa Martínez-Pérez, Albert Villoria, Fernando Bermejo, David Busquets, Blau Camps, Fiorella Cañete, Noemí Manceñido, David Monfort, Mercè Navarro-Llavat, José Lázaro Pérez-Calle, Laura Ramos, Montserrat Rivero, Teresa Angueira, Patricia Camo Monterde, Daniel Carpio, Irene García-de-la-Filia, Carlos González-Muñoza, Luis Hernández, José M Huguet, Víctor J Morales, Beatriz Sicilia, Pablo Vega, Isabel Vera, Yamile Zabana, Pilar Nos, Patricia Suárez Álvarez, Cristina Calviño-Suárez, Elena Ricart, Vicent Hernández, Miguel Mínguez, Lucía Márquez, Daniel Hervías Cruz, Saioa Rubio Iturria, Jesús Barrio, Carla Gargallo-Puyuelo, Rubén Francés, Esther Hinojosa, María del Moral, Xavier Calvet, Alicia Algaba, Xavier Aldeguer, Jordi Guardiola, Miriam Mañosa, Ramón Pajares, Marta Piqueras, Orlando García-Bosch, Pilar López Serrano, Beatriz Castro, Alfredo J Lucendo, Miguel Montoro, Elena Castro Ortiz, Francisco Mesonero, Esther García-Planella, David A Fuentes, Inmaculada Bort, Pedro Delgado-Guillena, Lara Arias, Agueda Iglesias, Marta Calvo, Maria Esteve, Eugeni Domènech, Javier P Gisbert
doi : 10.1093/ecco-jcc/jjab070
Journal of Crohn's and Colitis, Volume 15, Issue 11, November 2021, Pages 1846–1851
The development programm UNIFI has shown promising results of ustekinumab in ulcerative colitis [UC] treatment which should be confirmed in clinical practice. We aimed to evaluate the durability, effectiveness, and safety of ustekinumab in UC in real life.
Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials
Julian Panés, Séverine Vermeire, Marla C Dubinsky, Edward V Loftus, Jr, Nervin Lawendy, Wenjin Wang, Leonardo Salese, Chinyu Su, Irene Modesto, Xiang Guo, Jean-Frederic Colombel
doi : 10.1093/ecco-jcc/jjab065
Journal of Crohn's and Colitis, Volume 15, Issue 11, November 2021, Pages 1852–1863
Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. Here, we evaluate the efficacy and safety of tofacitinib re-treatment following treatment interruption in patients with ulcerative colitis.
Systematic Review: Sweet Syndrome Associated with Inflammatory Bowel Disease
Joseph Sleiman, Asif A Hitawala, Benjamin Cohen, Katie Falloon, Marian Simonson, Benjamin Click, Urmi Khanna, Anthony P Fernandez, Florian Rieder
doi : 10.1093/ecco-jcc/jjab079
Journal of Crohn's and Colitis, Volume 15, Issue 11, November 2021, Pages 1864–1876
Sweet syndrome [SS] is a dermatological condition associated with both inflammatory bowel disease [IBD] and azathioprine use. We performed a systematic review to better delineate clinical characteristics and outcomes of SS in IBD patients.
The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry
Manasi Agrawal, Xian Zhang, Erica J Brenner, Ryan C Ungaro, Michael D Kappelman, Jean-Frederic Colombel
doi : 10.1093/ecco-jcc/jjab071
Journal of Crohn's and Colitis, Volume 15, Issue 11, November 2021, Pages 1877–1884
The impact of immune-modifying therapies on outcomes of coronavirus disease 2019 [COVID-19] is variable. The purpose of this study was to determine the impact of vedolizumab [VDZ], a gut-selective anti-integrin, on COVID-19 outcomes in inflammatory bowel disease [IBD] patients.
Histopathological Features in Colonic Biopsies at Diagnosis Predict Long-term Disease Course in Patients with Crohn’s Disease
Ashkan Rezazadeh Ardabili, Danny Goudkade, Dion Wintjens, Mariëlle Romberg-Camps, Bjorn Winkens, Marie Pierik, Heike I Grabsch, Daisy Jonkers
doi : 10.1093/ecco-jcc/jjab087
Journal of Crohn's and Colitis, Volume 15, Issue 11, November 2021, Pages 1885–1897
Crohn’s disease [CD] is characterised by a heterogeneous disease course. Patient stratification at diagnosis using clinical, serological, or genetic markers does not predict disease course sufficiently to facilitate clinical decision making. The current study aimed to investigate the additive predictive value of histopathological features to discriminate between a long-term mild and severe disease course.
Identification of Three Novel Susceptibility Loci for Inflammatory Bowel Disease in Koreans in an Extended Genome-Wide Association Study
Seulgi Jung, Byong Duk Ye, Ho-Su Lee, Jiwon Baek, Gyeonghoon Kim, Dohoon Park, Sang Hyoung Park, Suk-Kyun Yang, Buhm Han, Jianjun Liu, Kyuyoung Song
doi : 10.1093/ecco-jcc/jjab060
Journal of Crohn's and Colitis, Volume 15, Issue 11, November 2021, Pages 1898–1907
Genome-wide association studies [GWAS] of inflammatory bowel disease [IBD] in multiple populations have identified over 240 susceptibility loci. We previously performed a largest-to-date Asian-specific IBD GWAS to identify two new IBD risk loci and confirm associations with 28 established loci. To identify additional susceptibility loci in Asians, we expanded our previous study design by doubling the case size with an additional dataset of 1726 cases and 378 controls.
Variants in STXBP3 are Associated with Very Early Onset Inflammatory Bowel Disease, Bilateral Sensorineural Hearing Loss and Immune Dysregulation
Jodie Ouahed, Judith R Kelsen, Waldo A Spessott, Kameron Kooshesh, Maria L Sanmillan, Noor Dawany, Kathleen E Sullivan, Kathryn E Hamilton, Voytek Slowik, Sergey Nejentsev, João Farela Neves, Helena Flores, Wendy K Chung, Ashley Wilson, Kwame Anyane-Yeboa, Karen Wou, Preti Jain, Michael Field, Sophia Tollefson, Maiah H Dent, Dalin Li, Takeo Naito, Dermot P B McGovern, Andrew C Kwong, Faith Taliaferro, Jose Ordovas-Montanes, Bruce H Horwitz, Daniel Kotlarz, Christoph Klein, Jonathan Evans, Jill Dorsey, Neil Warner, Abdul Elkadri, Aleixo M Muise, Jeffrey Goldsmith, Benjamin Thompson, Karin R Engelhardt, Andrew J Cant, Sophie Hambleton, Andrew Barclay, Agnes Toth-Petroczy, Dana Vuzman, Nikkola Carmichael, Corneliu Bodea, Christopher A Cassa, Marcella Devoto, Richard L Maas, Edward M Behrens, Claudio G Giraudo, Scott B Snapper
doi : 10.1093/ecco-jcc/jjab077
Journal of Crohn's and Colitis, Volume 15, Issue 11, November 2021, Pages 1908–1919
Very early onset inflammatory bowel disease [VEOIBD] is characterized by intestinal inflammation affecting infants and children less than 6 years of age. To date, over 60 monogenic aetiologies of VEOIBD have been identified, many characterized by highly penetrant recessive or dominant variants in underlying immune and/or epithelial pathways. We sought to identify the genetic cause of VEOIBD in a subset of patients with a unique clinical presentation.
Ustekinuma b for Crohn’s Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study
Tessa Straatmijer, Vince B C Biemans, Frank Hoentjen, Nanne K H de Boer, Alexander G L Bodelier, Gerard Dijkstra, Willemijn A van Dop, Jeoffrey J L Haans, Jeroen M Jansen, P W Jeroen Maljaars, Sander van der Marel, Bas Oldenburg, Cyriel Y Ponsioen, Marijn C Visschedijk, Annemarie C de Vries, Rachel L West, C Janneke van der Woude, Marieke Pierik, Marjolijn Duijvestein, Andrea E van der Meulen-de Jong
doi : 10.1093/ecco-jcc/jjab081
Journal of Crohn's and Colitis, Volume 15, Issue 11, November 2021, Pages 1920–1930
Ustekinumab is a monoclonal antibody that selectively targets p40, a shared subunit of the cytokines interleukin [IL]-12 and IL-23. It is registered for the treatment of inflammatory bowel diseases. We assessed the 2-year effectiveness and safety of ustekinumab in a real world, prospective cohort of patients with Crohn’s disease [CD].
Ustekinumab in Paediatric Patients with Moderately to Severely Active Crohn’s Disease: Pharmacokinetics, Safety, and Efficacy Results from UniStar, a Phase 1 Study
Joel R Rosh, Dan Turner, Anne Griffiths, Stanley A Cohen, Douglas Jacobstein, Omoniyi J Adedokun, Lakshmi Padgett, Natalie A Terry, Christopher O’Brien, Jeffrey S Hyams
doi : 10.1093/ecco-jcc/jjab089
Journal of Crohn's and Colitis, Volume 15, Issue 11, November 2021, Pages 1931–1942
The objective was to evaluate the pharmacokinetics, safety/tolerability, and efficacy of ustekinumab in children with moderately to severely active Crohn’s disease.
Suppressing Kv1.3 Ion Channel Activity with a Novel Small Molecule Inhibitor Ameliorates Inflammation in a Humanised Mouse Model of Ulcerative Colitis
Anna-Lena Unterweger, Morten Ø Jensen, Fabrizio Giordanetto, Vishwanath Jogini, Alena Rüschher, Marietta Seuß, Paula Winkelmann, Leandra Koletzko, David E Shaw, Matthias Siebeck, Roswitha Gropp, Florian Beigel, Attila Aszodi
doi : 10.1093/ecco-jcc/jjab078
Journal of Crohn's and Colitis, Volume 15, Issue 11, November 2021, Pages 1943–1958
The potassium channel Kv1.3 is a potentially attractive therapeutic target in T cell-mediated inflammatory diseases, as the activity of antigen-activated T cells is selectively impeded by Kv1.3 inhibition. In this study, we examined Kv1.3 as a potential therapeutic intervention point for ulcerative colitis [UC], and studied the efficacy of DES1, a small-molecule inhibitor of Kv1.3, in vitro and in vivo.
Immunological Networks Defining the Heterogeneity of Inflammatory Bowel Diseases
Katja A Selin, Charlotte R H Hedin, Eduardo J Villablanca
doi : 10.1093/ecco-jcc/jjab085
Journal of Crohn's and Colitis, Volume 15, Issue 11, November 2021, Pages 1959–1973
Current practice in IBD is to classify patients based on clinical signs and symptoms and provide treatments accordingly. However, the response of IBD patients to available treatments is highly variable, highlighting clinically significant heterogeneity among patients. Thus, more accurate patient stratification is urgently needed to more effectively target therapeutic interventions to specific patients. Here we review the degree of heterogeneity in IBD, discussing how the microbiota, genetics, and immune system may contribute to the variation among patients. We highlight how molecular heterogeneity may relate to clinical phenotype, but in other situations may be independent of clinical phenotype, encouraging future studies to fill the gaps. Finally, we discuss novel stratification methodologies as a foundation for precision medicine, in particular a novel stratification strategy based on conserved genes across species. All of these dimensions of heterogeneity have potential to provide strategies for patient stratification and move IBD practice towards personalised medicine.
